- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02672995
Fractionated Stereotactic Radiosurgery With Concurrent Bevacizumab for Brain Metastases: A Phase I Dose-escalation Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
For each group (two groups according to tumor size), the design proceeds with cohorts of three patients, with the first cohort treated at a starting dose. If none of the three patients in a cohort experiences a dose-limiting toxicity (DLT), the next cohort with three patients will be treated at the next higher dose level. If one of the first three patients experiences a dose-limiting toxicity, the next cohort will be treated at the same dose level. The dose escalation continues until at least two patients among a cohort of three to six patients experience DLTs and the maximum tolerated dose (MTD) will be the dose level just below. If the highest planned dose was achieved without two patients experiencing DLTs, the MTD will be that dose level.
The DLT is defined as grade 4 or above toxicities according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 within 4 months after stereotactic radiosurgery (SRS):
Grade 4 central nervous system necrosis (life-threatening consequences; urgent intervention indicated) Grade 4 sensory or motor neuropathy (life-threatening consequences; urgent intervention indicated) Grade 4 hemorrhage (life-threatening consequences; urgent intervention indicated) or Grade 4 thromboembolic event (life-threatening consequences such as pulmonary embolism, cerebrovascular event, arterial insufficiency; hemodynamic or neurologic instability; urgent intervention indicated) Grade 4 hypertension (life-threatening consequences such as malignant hypertension, transient or permanent neurologic deficit, hypertensive crisis; urgent intervention indicated)
Study treatment:
Fractionated stereotactic radiosurgery:
Group 1: tumors 1.5~2.5 cm in diameter Dose level 1: 21 Gy in 3 fractions Dose level 2: 24 Gy in 3 fractions Dose level 3: 27 Gy in 3 fractions Group 2: tumors 2.5~3.5 cm in diameter Dose level 1: 18 Gy in 3 fractions Dose level 2: 21 Gy in 3 fractions Dose level 3: 24 Gy in 3 fractions Three fractions will be given in one week with at least 1 day break.
Concurrent bevacizumab:
Bevacizumab 7.5 mg/kg will be given one day before the first fraction of radiosurgery and 2 weeks after the first dose of bevacizumab.
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Chia-Chun Wang, MD
- Email: chiachun@ntuh.gov.tw
Study Contact Backup
- Name: Feng-Ming Hsu
Study Locations
-
-
-
Taipei, Taiwan, 100
- Recruiting
- National Taiwan University Hospital
-
Contact:
- Chia-Chun Wang
- Email: chiachun@ntuh.gov.tw
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria
To be eligible for inclusion, patients must fulfill the following criteria:
- Patients with a histologic diagnosis of non-hematopoietic malignancy and radiographic evidence of measurable brain metastases (1.5~3.5 cm).
- The number of brain metastases receiving fractionated SRS: ≤3.
- No evidence of leptomeningeal metastasis on gadolinium-enhanced MRI within 30 days prior registration.
- Age ≥ 20 years.
- Karnofsky Performance Status ≥ 60.
- Life expectancy of ≥ 4 months.
- Women of childbearing potential and male participants must practice adequate contraception.
- Patients must be able to comply with the study protocol and follow-up schedules and provide study-specific informed consent.
Exclusion criteria Patients fulfill any of the following criteria will be excluded from this trial
- Serum creatinine > 2.0 mg/dL within 30 days prior registration
- Contraindication to magnetic resonance (MR) imaging such as implanted metal devices or foreign bodies, severe claustrophobia
- Patients with evidence of bleeding diathesis or coagulopathy, international normalized ratio (INR) >1.5
- Patients who require the use of warfarin sodium > 1 mg
- Patients with active GI ulcers, GI bleeding, or active inflammatory bowel disease
- Patients with clinically significant cardiac disease (e.g., uncontrolled hypertension [blood pressure of >160/90 mmHg on medication], history of myocardial infarction or unstable angina within 12 months of registration), New York Heart Association (NYHA) Class II or greater congestive heart failure, unstable symptomatic arrhythmia requiring medication (subjects with chronic atrial arrhythmia, i.e., atrial fibrillation or paroxysmal supraventricular tachycardia) are not eligible
- Patients with a history of aneurysms, cerebrovascular accident (CVA) and arteriovenous malformations
- Patients with arterial thromboembolic events, including transient ischemic attack (TIA), or clinically significant peripheral artery disease within 6 months of registration
- Patients with serious, non-healing wound, ulcer, or current healing fracture
- Patients with a history of any type of fistula (vesicovaginal, gastrointestinal, etc) or gastrointestinal perforation
Severe, active comorbidities which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and adverse events of the protocol, or limit compliance with study requirements, defined as follows:
- Uncontrolled active infection requiring intravenous antibiotics at the time of registration
- Transmural myocardial infarction ≤ 6 months prior to registration
- Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects
- Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration
- Uncontrolled psychiatric disorder
- Will receive any other investigational agent or chemotherapy and/or target therapies during SRS
- Women of childbearing potential and male participants who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the radiation treatment involved in this study may be significantly teratogenic
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Single arm dose-escalation
Fractionated stereotactic radiosurgery: Group 1: tumors 1.5~2.5 cm in diameter Dose level 1: 21 Gy in 3 fractions Dose level 2: 24 Gy in 3 fractions Dose level 3: 27 Gy in 3 fractions Group 2: tumors 2.5~3.5 cm in diameter Dose level 1: 18 Gy in 3 fractions Dose level 2: 21 Gy in 3 fractions Dose level 3: 24 Gy in 3 fractions Three fractions will be given in one week with at least 1 day break. Concurrent bevacizumab: Bevacizumab 7.5 mg/kg will be given one day before the first fraction of radiosurgery and 2 weeks after the first dose of bevacizumab. |
Fractionated stereotactic radiosurgery: Group 1: tumors 1.5~2.5 cm in diameter Dose level 1: 21 Gy in 3 fractions Dose level 2: 24 Gy in 3 fractions Dose level 3: 27 Gy in 3 fractions Group 2: tumors 2.5~3.5 cm in diameter Dose level 1: 18 Gy in 3 fractions Dose level 2: 21 Gy in 3 fractions Dose level 3: 24 Gy in 3 fractions Three fractions will be given in one week with at least 1 day break.
Other Names:
Concurrent bevacizumab: Bevacizumab 7.5 mg/kg will be given one day before the first fraction of radiosurgery and 2 weeks after the first dose of bevacizumab.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum tolerated dose
Time Frame: 4 months
|
The maximum tolerated dose of fractionated stereotactic radiosurgery with concurrent bevacizumab for brain metastases.
|
4 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Response rate
Time Frame: 4 months
|
Response rate
|
4 months
|
Time to progression
Time Frame: 4 months
|
Time to progression
|
4 months
|
The incidence of radiation-induced adverse effects
Time Frame: 4 months
|
The incidence of radiation-induced adverse effects
|
4 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Chia-Chun Wang, National Taiwan University Hospital
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neoplasms
- Neoplasms by Site
- Central Nervous System Neoplasms
- Nervous System Neoplasms
- Brain Neoplasms
- Physiological Effects of Drugs
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Bevacizumab
Other Study ID Numbers
- 201511005MINB
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Brain Neoplasm
-
Mayo ClinicNational Cancer Institute (NCI)CompletedMetastatic Malignant Neoplasm in the Brain | Recurrent Brain Neoplasm | Central Nervous System Neoplasm | Localized Brain NeoplasmUnited States
-
M.D. Anderson Cancer CenterRecruitingMetastatic Malignant Neoplasm in the Brain | Central Nervous System Neoplasm | Leptomeningeal Neoplasm | Primary Brain NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); University of HoustonRecruitingBrain Neoplasm | Metastatic Malignant Neoplasm in the Brain | Recurrent Brain NeoplasmUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingMetastatic Malignant Neoplasm in the Brain | Malignant Brain Neoplasm | Recurrent Malignant Brain NeoplasmUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedMetastatic Malignant Neoplasm in the Brain | Recurrent Brain Neoplasm | Primary Brain NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Recurrent Brain Neoplasm | Refractory Brain NeoplasmUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingMalignant Brain Neoplasm | Recurrent Malignant Brain Neoplasm | Refractory Malignant Brain NeoplasmUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingMetastatic Malignant Solid Neoplasm | Metastatic Malignant Neoplasm in the BrainUnited States
-
National Cancer Institute (NCI)Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Metastatic Malignant Neoplasm in the BrainUnited States
-
Dana-Farber Cancer InstituteBrigham and Women's HospitalCompletedMalignant Childhood Central Nervous System NeoplasmUnited States
Clinical Trials on Fractionated stereotactic radiosurgery
-
University of Erlangen-Nürnberg Medical SchoolRecruitingCerebral Metastases of Solid CancersGermany
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingMetastatic Malignant Neoplasm in the BrainUnited States, Canada
-
Steven BurtonActive, not recruiting
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)RecruitingMelanoma | Renal Cell Carcinoma | NSCLC | SCLC | Breast Carcinoma | Non-small Cell Lung Cancer | Small-cell Lung Cancer | Brain Metastases, AdultUnited States
-
Stanford UniversityCompletedNeoplasm Metastasis | Brain Cancer | Cancer of Brain and Nervous System | Metastatic Malignant Neoplasm to BrainUnited States
-
NYU Langone HealthCompletedIntracranial Arteriovenous Malformations (AVM)
-
Henry Ford Health SystemRecruitingGlioma | Glioblastoma | Astrocytoma | Malignant Glioma of Brain | Brain Cancer | Brain Tumor | Glioblastoma Multiforme | GBM | Malignant AstrocytomaUnited States
-
University of Michigan Rogel Cancer CenterCompleted
-
Accuray IncorporatedUniversity of PittsburghUnknownNon-small Cell Lung CancerUnited States, China
-
University of Alabama at BirminghamCompletedBrain MetastasesUnited States